New immunotherapy targeting infectious disease agent improves MS symptoms
A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has improved symptoms and quality of life for the majority of patients.
AID researchers are drawn from infectious disease experts from across QIMR and UQ who apply leading technologies to identify, understand and prevent infectious disease.
The core AID research themes are bacterial, viral, parasitic and fungal infectious diseases afflicting humans. This microbial pathogenesis research effort brings together basic science and clinical research.
AID links molecular microbiological and clinical expertise from the UQ Faculties of Science and Health Sciences, and UQCCR, UQCCHR, IMB, AIBN and the Diamantina Institute.
Kirsty's success going viral
Flu researcher Dr Kirsty Short has won a $25,000 fellowship for her work on the long-term links between obesity, the immune system and influenza... read more
more news and events
U.S. Challenges World to Intensify Global Fight Against Antibiotic Resistance
The United States announced today, during the United Nations General Assembly in New York, The AMR Challenge - the most ambitious global initiative to date to combat the growing threat of antibiotic resistance.. ... read more
Potential medical breakthroughs receive national funding
The world's next big medical breakthroughs could be in the hands of four University of Queensland researchers, announced as National Health and Medical Research Council Development Grant recipients.... read more